Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 8, Issue 2, Pages 175-181Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.8.2.175
Keywords
capromab pendetide; ProstaScint (R); prostate-specific membrane antigen; radioimmunoscintigraphy
Categories
Ask authors/readers for more resources
The provision of accurate prognostic information is a long-standing goal for effective management of prostate adenocarcinoma. Nontargeted imaging modalities are less efficient at detecting slow-growing prostate cancers. Prostate-specific membrane antigen has emerged as a superior biomarker, especially for the evaluation of metastatic spread. Advances in imaging technology have focused clinical interest on indium-111 capromab (In-111 capromab) pendetide, a radioimmunoconjugate that detects prostate-specific membrane antigen expression in vivo. Single-photon emission computed tomography capromab pendetide images, fused with those generated by computed tomography or magnetic resonance, have engendered improvements in localization accuracy by correlating high signal intensity with anatomic structures. In long-term outcomes studies, fused In-111 capromab pendetide scans have delivered
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available